TRAIL/Apo2L mediates the release of procoagulant endothelial microparticles induced by thrombin in vitro: a potential mechanism linking inflammation and coagulation.
[en] Microparticles are small vesicles playing a crucial role in cell communication by promoting prothrombotic and proinflammatory responses. However, the molecular mechanisms underlying their release are still elusive. We previously established that thrombin promoted the generation of endothelial microparticles (EMPs). In the present study, gene profiling identified TRAIL/Apo2L, a cytokine belonging to the tumor necrosis factor-alpha superfamily, as a target of thrombin. Thrombin increased the expression of cell-associated and soluble forms of TRAIL (sTRAIL) in HMEC-1 cells and human umbilical vein endothelial cells (HUVECs). Blocking TRAIL by specific antibodies or by small interfering RNA reduced both the number and the procoagulant activity of EMPs released by thrombin. Consistent with an involvement of sTRAIL in thrombin-induced EMP release, we showed that (1) exogenously added sTRAIL generated procoagulant EMPs; (2) supernatants from thrombin-stimulated endothelial cells induced EMP release by HMEC-1 cells and HUVECs, whereas those recovered from TRAIL knockdown endothelial cells displayed no effect. TRAIL/TRAIL-R2 complex mediated EMP release by initiating the recruitment of adaptor proteins and the activation of nuclear factor kappaB. Moreover, sTRAIL modulated intercellular adhesion molecule-1 and interleukin-8 expression induced by thrombin by a downstream pathway involving nuclear factor kappaB activation. Our data reveal a novel mechanism controlling EMP release and identify TRAIL as a key partner in the pathway linking coagulation and inflammation elicited by thrombin.
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Simoncini, Stephanie ✱; Faculte de Pharmacie, Institut National de la Santé et de la Recherche Médicale UMR608, Physiopathologie de l'Endothelium, Universite Mediterranee, Marseille, France
Njock, Makon-Sébastien ✱; Faculte de Pharmacie, Institut National de la Santé et de la Recherche Médicale UMR608, Physiopathologie de l'Endothelium, Universite Mediterranee, Marseille, France
Robert, Stephane; Faculte de Pharmacie, Institut National de la Santé et de la Recherche Médicale UMR608, Physiopathologie de l'Endothelium, Universite Mediterranee, Marseille, France
Camoin-Jau, Laurence; Faculte de Pharmacie, Institut National de la Santé et de la Recherche Médicale UMR608, Physiopathologie de l'Endothelium, Universite Mediterranee, Marseille, France
Sampol, Jose; Faculte de Pharmacie, Institut National de la Santé et de la Recherche Médicale UMR608, Physiopathologie de l'Endothelium, Universite Mediterranee, Marseille, France
Harle, Jean-Robert; Faculte de Pharmacie, Institut National de la Santé et de la Recherche Médicale UMR608, Physiopathologie de l'Endothelium, Universite Mediterranee, Marseille, France
Nguyen, Catherine; Institut National de la Sante et de la Recherche Medicale U928 (C.N.), Technologies Avancees pour le Genome et la Clinique, Marseille, France
Dignat-George, Francoise; Faculte de Pharmacie, Institut National de la Santé et de la Recherche Médicale UMR608, Physiopathologie de l'Endothelium, Universite Mediterranee, Marseille, France
Anfosso, Francine; Faculte de Pharmacie, Institut National de la Santé et de la Recherche Médicale UMR608, Physiopathologie de l'Endothelium, Universite Mediterranee, Marseille, France
✱ These authors have contributed equally to this work.
Language :
English
Title :
TRAIL/Apo2L mediates the release of procoagulant endothelial microparticles induced by thrombin in vitro: a potential mechanism linking inflammation and coagulation.
Publication date :
23 April 2009
Journal title :
Circulation Research
ISSN :
0009-7330
eISSN :
1524-4571
Publisher :
Lippincott Williams & Wilkins, United States - Maryland
Levi M, van der Poll T. Two-way interactions between inflammation and coagulation. Trends Cardiovasc Med. 2005;15:254-259.
Esmon CT. The impact of the inflammatory response on coagulation. Thromb Res. 2004;114:321-327.
Minami T, Sugiyama A, Wu SQ, Abid R, Kodama T, Aird WC. Thrombin and phenotypic modulation of the endothelium. Arterioscler Thromb Vasc Biol. 2004;24:41-53.
Sapet C, Simoncini S, Loriod B, Puthier D, Sampol J, Nguyen C, Dignat-George F, Anfosso F. Thrombin-induced endothelial microparticle generation: identification of a novel pathway involving ROCK-II activation by caspase-2. Blood. 2006;108:1868-1876.
Hugel B, Carmen M, Martinez MC, Kunzelmann C, Freyssinet JM. Membrane microparticles: two sides of the coin. Physiology. 2005;20: 22-27.
Combes V, Simon AC, Grau GE, Arnoux D, Camoin L, Sabatier F, Mutin M, Sanmarco M, Sampol J, Dignat-George F. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest. 1999;104:93-102.
Sabatier F, Roux V, Anfosso F, Camoin L, Sampol J, Dignat-George F. Interaction of endothelial microparticles with monocytic cells in vitro induces tissue factor-dependent procoagulant activity. Blood. 2002;99: 3962-3970.
Lacroix R, Sabatier F, Mialhe A, Basire A, Pannell R, Borghi H, Robert S, Lamy E, Plawinski L, Camoin-Jau L, Gurewich V, Angles-Cano E, Dignat-George F. Activation of plasminogen into plasmin at the surface of endothelial microparticles. Blood. 2007;110:2432-2439.
Taraboletti G, D'Ascenzo S, Borsotti P, Giavazzi R, Pavan A, Dolo V. Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells. Am J Pathol. 2002;160:673-680.
Sabatier F, Darmon P, Hugel B, Combes V, Sanmarco M, Velut JG, Arnoux D, Charpiot P, Freyssinet JM, Oliver C, Sampol J, Dignat-George F. Type 1 and type 2 diabetic patients display different patterns of cellular microparticles. Diabetes. 2002;51:2840-2845.
Dignat-George F, Camoin-Jau L, Sabatier F, Arnoux D, Anfosso F, Bardin N, Veit V, Combes V, Gentile S, Moal V, Sanmarco M, Sampol J. Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome. Thromb Haemost. 2004; 91:667-673.
Faure V, Dou L, Sabatier F, Cerini C, Sampol J, Berland Y, Brunet P, Dignat-George F. Elevation of circulating endothelial microparticles in patients with chronic renal failure. J Thromb Haemost. 2006;4:566-573.
Shet AS, Aras O, Gupta K, Hass MJ, Rausch DJ, Saba N, Koopmeiners L, Key NS, Hebbel RP. Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood. 2003;102:2678-2683.
Bernal-Mizrachi L, Jy W, Fierro C, Macdonough R, Velazques HA, Purow J, Jimenez JJ, Horstman LL, Ferreira A, de Marchena E, Ahn YS. Endothelial microparticles correlate with high-risk angiographic lesions in acute coronary syndromes. Int J Cardiol. 2004;97:439-446.
Svedas E, Nisell H, VanWijk MJ, Nikas Y, Kublickiene KR. Endothelial dysfunction in uterine circulation in preeclampsia .Am J Obstet Gynecol. 2002;187:1608-1616.
Schaefer U, Voloshanenko O, Willen D, and Walczak H. TRAIL: a multifunctional cytokine. Front Biosc. 2007;12:3813-3824.
Zauli G, Secchiero P. The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology. Cytokine Growth Factor Rev. 2006;17:245-257.
Kimberley FC, Screaton GR. Following a TRAIL: update on a ligand and its five receptors. Cell Res. 2004;14:359-372.
Varfolomeev E, Maecker H, Sharp D, Lawrence D, Renz M, Vucic D, Ashkenazi A. Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing Ligand. J Biol Chem. 2005;280:40599-40608.
Aird WC. Phenotypic heterogeneity of the endothelium. Circ Res. 2007; 100:158-173.
Greinacher A, Warkentin TE. The direct thrombin inhibitor hirudin. Thromb Haemost. 2008;99:819-829.
Wu SQ, Aird WC. Thrombin, TNF-{alpha}, and LPS exert overlapping but nonidentical effects on gene expression in endothelial cells and vascular smooth muscle cells. Am J Physiol Heart Circ Physiol. 2005; 289:H873-H885.
Muhlenbeck F, Schneider P, Bodmer JL, Schwenzer R, Hauser A, Schubert G, Scheurich P, Moosmayer D, Tschopp J, Wajant H. The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation. J Biol Chem. 2000; 275:32208-32213.
Wajant H, Moosmayer D, Wuest T, Bartke T, Gerlach E, Schonherr U, Peters N, Scheurich P, Pfizenmaier K. Differential activation of TRAIL-R1 and-2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative. Oncogene. 2001;20:4101-4106.
Kuang AA, Diehl GE, Zhang JK, Winoto A. FADD is required for DR4-and DR5-mediated apoptosis. J Biol Chem. 2000;275:25065-25068.
Schneider P, Thome M, Burns K, Bodmer JL, Hofmann K, Kataoka T, Holler N, Tschopp J. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF--B. Immunity. 1997;7: 831-836.
Kelliher MA, Grimm S, Ishida Y, Kuo F, Stanger BZ, Leder P. The death domain kinase RIP mediates the TNF-induced NF-kappa B signal. Immunity. 1998;8:297-303.
Harper N, Farrow SN, Kaptein A, Cohen GM, MacFarlane M. Modulation of tumor necrosis factor apoptosis-inducing ligand-induced NF-kappa B activation by inhibition of apical caspases. J Biol Chem. 2001;276:34743-34752.
Wajant H. TRAIL and NF-B signaling-a complex relationship. Vitam Horm. 2004;67:103-132.
Kaplanski G, Fabrigoule M, Boulay V, Dinarello CA, Bongrand P, Kaplanski S, Farnarier C. Thrombin induces endothelial type II activation in vitro. J Immunol. 1997;158:5435-5441.
Li JH, Kirkiles-Smith NC, McNiff JM, Pober JS. TRAIL induces apo-ptosis and inflammatory gene expression in human endothelial cells. J Immunol. 2003;171:1526-1533.
Wachter T, Sprick M, Hausmann D, Kerstan A, McPherson K, Stassi G, Brocker EB, Walczak H, Leverkus M. cFLIPL inhibits tumor necrosis factor-related apoptosis-inducing ligand-mediated NF-kappaB activation at the death-inducing signaling complex in human keratinocytes. J Biol Chem. 2004;279:52824-52834.
Chaudhari B, Murphy R, Agrawal D. Following the TRAIL to apoptosis. Immunol Res. 2006;35:249-262.
Secchiero P, Gonelli A, Carnevale E, Milani D, Pandolfi A, Zella D, Zauli G. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation. 2003;107:2250-2256.
Secchiero P, Gonelli A, Carnevale E, Corallini F, Rizzardi C, Zacchigna S, Melato M, Zauli G. Evidence for a proangiogenic activity of TNF-related apoptosis-inducing ligand. Neoplasia. 2004;6:364-373.
O'Brien LA, Richardson MA, Mehrbod SF, Berg DT, Gerlitz B, Gupta A, Grinnell BW. Activated protein c decreases tumor necrosis factor-related apoptosis-inducing ligand by an EPCR-Independent mechanism involving Egr-1/Erk-1/2 activation. Arterioscler Thromb Vasc Biol. 2007; 27:2634-2641.
Chen P, and Easton A. Apoptotic phenotype alters the capacity of tumor necrosis factor-related apoptosis-inducing ligand to induce human vascular endothelial activation. J Vasc Res. 2007;45:111-122.
Martin-Ventura JL, Munoz-Garcia B, Egido J, and Blanco-Colio LM. TRAIL and vascular injury. Front Biosc. 2007;12:3656-3667.
Lub-de Hooge MN, de Vries EGE, de Jong S, Bijl M. Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus. Ann Rheum Dis. 2005;64:854-858.
Lub-de Hooge MN, de Jong S, Vermot-Desroches C, Tulleken JE, de Vries EGE, Zijlstra JG. Endotoxin increases plasma soluble tumor necrosis factor-related apoptosis-inducing ligand level mediated by the p38 mitogen-activated protein kinase signaling pathway. Shock. 2004;22: 186-188.
Morel J, Audo R, Hahne M, Combe B. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt. J Biol Chem. 2005; 280:15709-15718.
Berckmans RJ, Nieuwland R, Tak PP, Boing AN, Romijn FPHT, Kraan MC, Breedveld FC, Hack CE, Sturk A. Cell-derived microparticles in synovial fluid from inflamed arthritic joints support coagulation exclusively via a factor VII-dependent mechanism. Arthr Rheum. 2002;46: 2857-2866.
Soriano AO, Jy WC, Chirinos JA, Valdivia MA, Velasquez HS, Jimenez JJ, Horstman LL, Kett DH, Schein RMH, Ahn YS. Levels of endothelial and platelet microparticles and their interactions with leukocytes negatively correlate with organ dysfunction and predict mortality in severe sepsis. Crit Care Med. 2005;33:2540-2546.
VanWijk MJ, VanBavel E, Sturk A, Nieuwland R. Microparticles in cardiovascular diseases. Cardiovasc Res. 2003;59:277-287.
Mallat Z, Hugel B, Ohan J, Leseche G, Freyssinet JM, Tedgui A. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques. Circulation. 1999;99:348-353.
Leroyer AS, Isobe H, Leseche G, Castier Y, Wassef M, Mallat Z, Binder BR, Tedgui A, Boulanger CM. Cellular origins and thrombogenic activity of microparticles isolated from human atherosclerotic plaques. J Am Coll Cardiol. 2007;49:772-777.
Kavurma MM, Bennett MR. Expression, regulation and function of trail in atherosclerosis. Biochem Pharmacol. 2008;75:1441-1450.
Michowitz Y, Goldstein E, Roth A, Afek A, Abashidze A, Ben Gal Y, Keren G, George J. The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis. J Am Coll Cardiol. 2005;45:1018-1024.
Schoppet M, Sattler AM, Schaefer JR, Hofbauer LC. Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in atherosclerosis. Atherosclerosis. 2006;184:446-447.
